Rich S, Hart K, Kieras K, Brundage B H
Chest. 1987 Mar;91(3):356-60. doi: 10.1378/chest.91.3.356.
Thromboxane synthetase inhibitors have been shown to reduce thromboxane, a potent vasoconstrictor, and increase prostacyclin, a potent vasodilator, in normal subjects. We evaluated the acute and chronic (three months) effects of the thromboxane synthetase inhibitor CGS13080 administered 200 mg every six hours on the resting hemodynamics in ten patients with primary pulmonary hypertension (PPH), and on their response to 20 mg of nifedipine given sublingually before and after the thromboxane synthetase inhibitor treatment. It was concluded that one can modulate the levels of endogenous thromboxane and prostacyclin in patients with primary pulmonary hypertension using a thromboxane synthetase inhibitor. Although the thromboxane synthetase inhibitor alone produced only modest hemodynamic changes over time, the addition of nifedipine was able to produce a further lowering of pulmonary artery pressure and pulmonary vascular resistance.
在正常受试者中，血栓素合成酶抑制剂已被证明可降低血栓素（一种强效血管收缩剂），并增加前列环素（一种强效血管舒张剂）。我们评估了每6小时服用200毫克血栓素合成酶抑制剂CGS13080对10例原发性肺动脉高压（PPH）患者静息血流动力学的急性和慢性（三个月）影响，以及对在血栓素合成酶抑制剂治疗前后舌下含服20毫克硝苯地平的反应。得出的结论是，使用血栓素合成酶抑制剂可以调节原发性肺动脉高压患者体内内源性血栓素和前列环素的水平。尽管单独使用血栓素合成酶抑制剂随时间推移仅产生适度的血流动力学变化，但加用硝苯地平能够进一步降低肺动脉压和肺血管阻力。
